Skip to main content
    M

    Myriad Genetics Inc (MYGN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $5.57
    -0.09 (-1.59%)

    Market Cap: $542.92M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Myriad Genetics Inc (MYGN) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Myriad Genetics (MYGN) trades at 0.7x sales and 2.0x book value. Its P/S of 0.7x is below its 5-year median of 2.1x. Its forward P/E is 54.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E54.0x
    Price to sales0.7x
    Price to book2.0x
    PEGN/A
    FCF yield-6.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 70.8% below 2.4x and its P/B is in line.

    MultipleCurrent5-year median10-year median
    P/S0.7x2.1x2.4x
    P/B2.0x1.9x2.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/E, its P/E ranged from 13.7x in 2016 to 105.5x in 2024. 2024 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$6.15N/A0.7x1.6x
    2024$13.71105.5x1.5x1.8x
    2023$19.14N/A2.1x2.1x
    2022$14.51N/A1.7x1.3x
    2021$27.60N/A3.1x2.3x
    2020$19.78N/A2.8x1.7x
    2019$27.2323.1x2.8x1.9x
    2018$29.0719.4x2.6x2.0x
    2017$34.3530.1x3.3x2.6x
    2016$16.6713.7x1.6x1.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MYGN

    What is MYGN's forward P/E ratio?

    Myriad Genetics has a forward P/E ratio of 54.0x.

    Is MYGN stock overvalued?

    GNG's valuation label for MYGN is Undervalued.

    What is MYGN's price to sales ratio?

    Myriad Genetics has a price to sales ratio of 0.7x.